Rizatriptan 1,2-(4-dimethylamino)butane
|
- $140 - $2000
- Product name: Rizatriptan 1,2-(4-dimethylamino)butane
- CAS: 1135479-41-2
- MF: C36H49N11
- MW: 635.85
- EINECS:
- MDL Number:
- Synonyms:Rizatriptan 1,2-(4-dimethylamino)butane ;Rizatriptan Impurity 4;1H-Indole-1-butanamine, 3-[2-(dimethylamino)ethyl]-δ-[3-[2-(dimethylamino)ethyl]-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-2-yl]-N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-;Tylosin Impurity 4 (Tylvalosin)
4 prices
Selected condition：
Brand
- Medical Isotopes, Inc.
- TRC
Package
- 10mg
- 100mg
- ManufacturerMedical Isotopes, Inc.
- Product number66973
- Product descriptionRizatriptan1,2-(4-dimethylamino)butane
- Packaging10mg
- Price$625
- Updated2021-12-16
- Buy
- ManufacturerMedical Isotopes, Inc.
- Product number66973
- Product descriptionRizatriptan1,2-(4-dimethylamino)butane
- Packaging100mg
- Price$2000
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberR545020
- Product descriptionRizatriptan1,2-(4-Dimethylamino)butane
- Packaging10mg
- Price$140
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberR545020
- Product descriptionRizatriptan1,2-(4-Dimethylamino)butane
- Packaging100mg
- Price$1100
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Medical Isotopes, Inc. | 66973 | Rizatriptan1,2-(4-dimethylamino)butane | 10mg | $625 | 2021-12-16 | Buy |
| Medical Isotopes, Inc. | 66973 | Rizatriptan1,2-(4-dimethylamino)butane | 100mg | $2000 | 2021-12-16 | Buy |
| TRC | R545020 | Rizatriptan1,2-(4-Dimethylamino)butane | 10mg | $140 | 2021-12-16 | Buy |
| TRC | R545020 | Rizatriptan1,2-(4-Dimethylamino)butane | 100mg | $1100 | 2021-12-16 | Buy |
Properties
Boiling point :847.8±75.0 °C(Predicted)
Density :1.21±0.1 g/cm3(Predicted)
pka :17.07±0.30(Predicted)
Density :1.21±0.1 g/cm3(Predicted)
pka :17.07±0.30(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|